Common Contracts
3 similar null contracts by PW Medtech Group LTD
IRREVOCABLE UNDERTAKINGPW Medtech Group LTD • October 28th, 2020 • Biological products, (no disgnostic substances)
WHEREAS, on the date hereof, the Company and Biomedical Treasure Limited (“Biomedical Treasure”) entered into a share purchase agreement (the “PWM-Biomedical Treasure SPA”), pursuant to and subject to the terms and conditions of which the Company agrees to sell to Biomedical Treasure, and Biomedical Treasure agrees to purchase from the Company 3,750,000 ordinary shares of the Target (all the obligations of the Company under the PWM-Biomedical Treasure SPA the performance of which by the Company is subject to and contingent upon the approval of the shareholders of the Company in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Hong Kong Listing Rules”) are collectively referred to as the “PWM Share Sale Obligations”);
IRREVOCABLE UNDERTAKINGPW Medtech Group LTD • October 28th, 2020 • Biological products, (no disgnostic substances) • Hong Kong
WHEREAS, on the date hereof, the Company and 2019B Cayman Limited (“2019B Cayman”) entered into a share purchase agreement (the “PWM-2019B Cayman SPA”), pursuant to and subject to the terms and conditions of which the Company agrees to sell to 2019B Cayman, and 2019B Cayman agrees to purchase from the Company 910,167 ordinary shares of the Target (all the obligations of the Company under the PWM-2019B Cayman SPA the performance of which by the Company is subject to and contingent upon the approval of the shareholders of the Company in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Hong Kong Listing Rules”) are collectively referred to as the “PWM Share Sale Obligations”);
IRREVOCABLE UNDERTAKINGPW Medtech Group LTD • October 28th, 2020 • Biological products, (no disgnostic substances) • Hong Kong
WHEREAS, on the date hereof, the Company and Biomedical Future Limited (“Biomedical Future”) entered into a share purchase agreement (the “PWM-Biomedical Future SPA”), pursuant to and subject to the terms and conditions of which the Company agrees to sell to Biomedical Future, and Biomedical Future agrees to purchase from the Company 660,833 ordinary shares of the Target (which may increase to up to 1,571,000 ordinary shares of the Target in the aggregate pursuant to the terms and conditions of the PWM-Biomedical Future SPA) (all the obligations of the Company under the PWM-Biomedical Future SPA the performance of which by the Company is subject to and contingent upon the approval of the shareholders of the Company in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Hong Kong Listing Rules”) are collectively referred to as the “PWM Share Sale Obligations”);
